Daelung Pharmaceuticals Unveils Innovative Drug Delivery Technologies at PODD Conference
Daelung Pharmaceuticals (069620) has showcased its cutting-edge drug delivery technologies, aiming to reduce administration frequency, minimize injection volume, and diversify delivery methods. By leveraging three distinct drug delivery platforms tailored to various medication characteristics, the company seeks to expand its joint development opportunities with global pharmaceutical and biotech firms.
On October 29-30, Daelung Pharmaceuticals participated in the international drug delivery technology conference, 'PODD (Partnership Opportunities in Drug Delivery) 2026,' held in Boston, USA. On November 2nd, the company announced its presentation of research outcomes for three next-generation drug delivery platforms.
Long-Acting Injections, Micro-Needle Patches, and High-Concentration Biopharmaceutical Formulations
Daelung Pharmaceuticals has demonstrated its commitment to enhancing drug delivery by presenting its advancements in long-acting injections, micro-needle patches, and high-concentration biopharmaceutical formulations. These innovative platforms offer the potential to reduce the frequency of drug administration, minimize injection volumes, and provide a range of delivery options.
The company's participation in the PODD conference allowed it to engage in one-on-one partnering discussions with global pharmaceutical and biotech companies, exploring opportunities for joint development and commercialization of these novel drug delivery technologies.
Research Outcomes and Global Impact
Daelung Pharmaceuticals shared its research findings, highlighting the potential of its drug delivery platforms to improve the formulation and pharmacokinetics of peptide and biopharmaceutical drugs. By showcasing these advancements, the company aims to establish itself as a key player in the global pharmaceutical market, offering innovative solutions to enhance drug efficacy and patient convenience.
With its participation in prestigious international conferences like PODD, Daelung Pharmaceuticals solidifies its position as a leader in drug delivery technologies, attracting interest from potential partners and investors. The company's dedication to research and development positions it well to capitalize on the growing demand for advanced drug delivery systems.
Long-Acting Injection Platform 'CURE', Microneedle Platform 'CLOPAM', and High-Concentration Biopharmaceutical Formulation Platform 'Thermicra' Unveiled
At the event, three key technologies were revealed: the long-acting injection platform 'CURE', the microneedle platform 'CLOPAM', and the biopharmaceutical high-concentration formulation platform 'Thermicra'. Each of these platforms focuses on specific aspects of drug delivery, including sustained release, transdermal delivery, and the development of high-concentration formulations.
Reducing Administration Frequency and Improving Delivery Methods
The primary objective of these three platforms presented by Daewoong Pharmaceutical is to enhance therapeutic convenience by implementing drug delivery methods tailored to the characteristics of each medication. While the common goal remains consistent, there are variations in the target applications and technical approaches.
Platform 'CURE': Focus on Reducing Administration Frequency
The first technology, platform 'CURE', is designed to reduce the frequency of drug administration. It utilizes biodegradable microparticles made from a specific polymer to ensure a sustained release of the medication over an extended period. The company has announced the results of pharmacokinetic studies applying this technology to peptide drugs, along with the development of formulations and processes considering large-scale production.
Innovative Drug Delivery Technologies Unveiled
Micro-Needle Platform: A Game-Changer for Medication Administration
The introduction of the CloPham micro-needle platform marked a significant advancement in drug delivery methods. This patch-type technology utilizes microscopic needles to deliver medication through the skin, offering a novel approach for treating obesity and diabetes with GLP-1-based drugs.
Daewoong Pharmaceutical disclosed the results of its evaluation, showcasing the drug absorption and blood concentration changes post-patch administration using CloPham. The company also highlighted its achievements in precision manufacturing and automated process development.
High-Concentration Formulation Platform: Reducing Injection Volumes
The high-concentration formulation platform, SurmiCrada, aims to reduce the volume of biopharmaceutical injections. By formulating antibodies and other biopharmaceuticals at high concentrations, this technology enables subcutaneous administration with minimal volume.
At the event, the application of SurmiCrada to antibodies and antibody-drug conjugates (ADCs) was presented, along with the development of high-concentration formulations. The research outcomes, evaluating drug absorption and activity within the body, were also shared.
Tailored Applications for Different Drugs and Purposes
The applicability of these technologies varies depending on the type of drug and the development objective. Daewoong Pharmaceutical is concurrently researching the necessary technologies and manufacturing processes for sustained release, skin delivery, and high-concentration formulations, thereby expanding the scope of its platforms.
Global Pharmaceutical Giants Eye Daelung's Drug Delivery Platform for Candidate Assets
Daelung Pharmaceutical Co. aims to leverage its industry connections from the recent event to forge subsequent technology collaborations. Beyond its own in-house R&D, the company is exploring business opportunities by applying its drug delivery platform to candidate assets held by external pharmaceutical and biotech firms.
During the event, Daelung operated an exhibition booth and conducted individual business meetings with global pharmaceutical and biotech companies. The company showcased the technical characteristics and research outcomes of its platforms and gauged interest and demand for future collaborations.
Daelung plans to review options to improve dosing frequency, administration methods, and volume by selecting the most suitable formulation technology based on the characteristics and development stage of each drug. Building on this, the company will work with its partners to refine product differentiation strategies for candidate assets and expand opportunities for joint development collaborations.
"To enhance the competitiveness of our novel drugs, it is crucial to have delivery technologies optimized for the characteristics of each drug, as well as the formulation and manufacturing capabilities to translate these into actual products," said Sung-Soo Park, CEO of Daelung Pharmaceutical. "Having showcased Daelung's next-generation drug delivery technologies and R&D capabilities at PODD 2026, we aim to forge genuine business partnerships with global pharmaceutical companies by offering tailored platforms for their candidate assets."
Market Visual
Late-Session Selling Pressure Weighs on Markets
In early trade, the markets witnessed a wave of selling pressure, with investors booking profits and triggering margin call liquidations. This late-session activity erased intraday gains, leaving the indices in the red.
[Photo caption: Kim Kwan-young, head of Daewoong Pharmaceutical's Formulation Technology Center, presents on next-generation drug delivery platform technologies at PODD 2026. /Photo provided by Daewoong Pharmaceutical]
The commercialization of innovative drug delivery systems is a key focus for pharmaceutical companies, and Daewoong Pharmaceutical's platform technologies are gaining attention. However, market participants remain cautious, leading to a pullback in the pharmaceutical sector.
As yield rates continue to rise, investors are closely monitoring the impact on the broader market. The late-session sell-off indicates a potential shift in sentiment, with further volatility expected in the coming days.
